Wiens Brian L
Myogen Inc., 7575 W 103rd Ave, #102, Westminster, CO 80021, USA.
Pharm Stat. 2006 Oct-Dec;5(4):265-71. doi: 10.1002/pst.214.
Noninferiority testing in clinical trials is commonly understood in a Neyman-Pearson framework, and has been discussed in a Bayesian framework as well. In this paper, we discuss noninferiority testing in a Fisherian framework, in which the only assumption necessary for inference is the assumption of randomization of treatments to study subjects. Randomization plays an important role in not only the design but also the analysis of clinical trials, no matter the underlying inferential field. The ability to utilize permutation tests depends on assumptions around exchangeability, and we discuss the possible uses of permutation tests in active control noninferiority analyses. The other practical implications of this paper are admittedly minor but lead to better understanding of the historical and philosophical development of active control noninferiority testing. The conclusion may also frame discussion of other complicated issues in noninferiority testing, such as the role of an intention to treat analysis.
临床试验中的非劣效性检验通常在奈曼 - 皮尔逊框架下被理解,同时也在贝叶斯框架下进行过讨论。在本文中,我们讨论费希尔框架下的非劣效性检验,在该框架中,进行推断所需的唯一假设是将治疗随机分配给研究对象的假设。无论基础推断领域如何,随机化不仅在临床试验的设计中,而且在其分析中都起着重要作用。利用置换检验的能力取决于关于可交换性的假设,并且我们讨论了置换检验在活性对照非劣效性分析中的可能用途。诚然,本文的其他实际意义较小,但有助于更好地理解活性对照非劣效性检验的历史和哲学发展。该结论也可能为非劣效性检验中其他复杂问题的讨论提供框架,例如意向性分析的作用。